Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cerebroprotein Hydrolysate for Injection is a biological extract developed and marketed by Shenzhen Mellow Hope Pharmaceutical Industrial. Derived from mammalian brain tissue, it consists of a complex mixture of low-molecular-weight peptides and amino acids. The drug is intended to support neurological recovery by promoting neuronal survival, stimulating neuroplasticity, and providing neuroprotective effects. It is primarily indicated for the treatment of craniocerebral trauma (traumatic brain injury) and various cerebrovascular diseases, including stroke and cognitive deficits. The product is administered via injection and has received regulatory approval in China, where the company is a significant exporter of biopharmaceuticals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cerebroprotein Hydrolysate for Injection.